Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310901 · ClinicalTrials.gov registry record · Phase 1
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
A Phase 1 study of Obese But Otherwise Healthy Participants, sponsored by Corbus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 15
- Study locations
NCT07310901: Recruiting Phase 1 study of Obese But Otherwise Healthy Participants, sponsored by Corbus Pharmaceuticals.
NCT07310901 is a Phase 1 study of Obese But Otherwise Healthy Participants that is actively recruiting participants, run by Corbus Pharmaceuticals. The registered enrollment target is 252 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (320% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07310901, a Phase 1 study of Obese But Otherwise Healthy Participants, is actively recruiting participants, sponsored by Corbus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.
Primary Outcome
Maximum plasma concentration (Cmax)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRB-913
Study Locations (15)
Florida
- Accel Research Sites - DeLand
- Tampa Bay Medical Research - Largo
- Quotient Sciences - Miami
New York
- Neurobehavioral Research - Cedarhurst
- Rochester Clinical Research - Rochester
Ohio
- Medpace Clinical Pharmacology - Cincinnati
- Velocity Clinical Research - Cleveland
Texas
- Velocity Clinical Research - Dallas
- Flourish Research - San Antonio
Alabama
- Central Alabama Research - Birmingham
Arizona
- Arizona Clinical Trials - Chandler
California
- Prospective Research Innovations - Rancho Cucamonga
Kentucky
- Louisville Metabolic and Atherosclerosis Research Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 1 |
What NCT07310901 shows while recruiting
NCT07310901 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (320% higher).
The record links to 1 condition, with Obese But Otherwise Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07310901 lists 15 locations in 10 states (Florida, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT07310901 about?
NCT07310901 is a clinical study titled "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity". This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects...
What is the current status of trial NCT07310901?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2025-12-04. Estimated completion is 2026-07-31.
What conditions does trial NCT07310901 study?
This clinical trial studies the following conditions: Obese But Otherwise Healthy Participants.
What interventions are being tested in trial NCT07310901?
The interventions under investigation include: Placebo (DRUG), CRB-913 (DRUG).
Who is sponsoring clinical trial NCT07310901?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310901 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obese But Otherwise Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07310901's enrollment target sits among peer trials
252 169th of 2000 higher than 1,829 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI